Astellas Retries Gene Therapy After Deaths
Fast facts
- Category: Health
- Language: EN
- Published: 2026-04-27 09:20 UTC
- Sources: Stat News
Pharmaceutical company Astellas is re-entering clinical trials with a next-generation gene therapy for XLMTM after previous deaths led to its suspension. The move comes as the biotech industry continues to push boundaries in genetic research.
Why it matters
- This update can influence the Health agenda over the next 24-48 hours.
- It is based on 1 source, which helps cross-check key claims quickly.
- Watch follow-up statements and market/public response to assess real impact.